{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:25:24Z","timestamp":1771262724975,"version":"3.50.1"},"reference-count":173,"publisher":"Sociedad Espanola de Patologia Digestiva (SEPD)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev Esp Enferm Dig"],"published-print":{"date-parts":[[2016]]},"DOI":"10.17235\/reed.2016.4232\/2016","type":"journal-article","created":{"date-parts":[[2016,3,29]],"date-time":"2016-03-29T19:59:47Z","timestamp":1459281587000},"page":"207-224","source":"Crossref","is-referenced-by-count":48,"title":["Proton-pump inhibitors adverse effects: a review of the evidence and position statement by the Sociedad Espa\u00f1ola de Patolog\u00eda Digestiva"],"prefix":"10.17235","volume":"108","author":[{"given":"Crist\u00f3bal","family":"de la Coba Ortiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Arg\u00fcelles Arias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Mart\u00edn de Argila de Prados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"J\u00fadez Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Linares Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aida","family":"Ortega Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Rodr\u00edguez de Santiago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Rodr\u00edguez-T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Isabel","family":"Vera Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Aguilera Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngel","family":"\u00c1lvarez S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal Jes\u00fas","family":"Andrade Bellido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fidencio","family":"Bao P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Castro Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Froil\u00e1n","family":"Giganto Tom\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6910","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363240-00004"},{"key":"ref2","unstructured":"2. Garc\u00eda del Pozo J. Estudio de utilizaci\u00f3n de antiulcerosos en Espa\u00f1a (2000-2008). Inf Ter Sist Nac Salud. 2009; 33: 49-54."},{"key":"ref3","unstructured":"3. Ministerio de Sanidad. Subgrupos ATC y Principios activos de mayor consumo en el Sistema Nacional de Salud en 2010. Inf Ter Sist Nac Salud. 2010; 35: 124-8."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4321\/S1130-01082013000300001"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. Simo Minana J. Use of prescription drugs in Spain and Europe. Aten Primaria. 2012; 44: 335-47. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22018798","DOI":"10.1016\/j.aprim.2011.06.009"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02454.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.49.4064"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"8. Walker NM, McDonald J. An evaluation of the use of proton pump inhibitors. Pharm World Sci. 2001; 23: 116-7. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11468876","DOI":"10.1023\/A:1011278030001"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9. de Burgos Lunar C, Novo del Castillo S, Llorente Diaz E, et al. Study of prescription-indication of proton pump inhibitors. Rev Clin Esp. 2006; 206: 266-70. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16762289","DOI":"10.1157\/13088585"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. Martin-Echevarria E, Pereira Julia A, Torralba M, et al. Assessing the use of proton pump inhibitors in an internal medicine department. Rev Esp Enferm Dig. 2008; 100: 76-81. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18366264","DOI":"10.4321\/S1130-01082008000200003"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2006.051151"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0871-9"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03628.x"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. Villamanan E, Ruano M, Lara C, et al. Reasons for initiation of proton pump inhibitor therapy for hospitalised patients and its impact on outpatient prescription in primary care. Rev Esp Enferm Dig. 2015; 107: 652-8. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26541654","DOI":"10.17235\/reed.2015.3882\/2015"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15. Ramirez E, Lei SH, Borobia AM, et al. Overuse of PPIs in patients at admission, during treatment, and at discharge in a tertiary Spanish hospital. Curr Clin Pharmacol. 2010; 5: 288-97. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20925644","DOI":"10.2174\/157488410793352067"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02973.x"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17. Ponce Romero M, Berenguer Lapuerta J. Current indications for proton pump inhibitors. Rev Clin Esp. 2003; 203: 136-8. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12646083","DOI":"10.1157\/13044924"},{"key":"ref18","unstructured":"18. Grupo de trabajo Sector Zaragoza I Salud. Empleo de los inhibidores de la bomba de protones en la prevenci\u00f3n de gastropat\u00edas secundarias a f\u00e1rmacos. Gu\u00eda de Pr\u00e1ctica Cl\u00ednica. 2012 (Enero) ed. Zaragoza: Gu\u00eda Salud.Accesible en: http:\/\/www.guiasalud.es\/GPC\/GPC_509_IBP_gastropatias_2rias_fcos_completa.pdf."},{"key":"ref19","unstructured":"19. Product Characteristics. Spanish Agency of Medicines and Medical Devices. Accesible en: http:\/\/www.aemps.gob.es\/cima\/fichasTecnicas.do?metodo=detalleForm."},{"key":"ref20","unstructured":"20. Arroyo Villarino M, Lanas Arbeloa A. Gastroenteropat\u00eda por AINE. En: Asociaci\u00f3n Espa\u00f1ola de Gastroenterolog\u00eda, Ponce Garcia J., editor. Tratamiento de las enfermedades gastroenterol\u00f3gicas. Barcelona: Elsevier; 2011. p. 123-31."},{"key":"ref21","unstructured":"21. P\u00e9rez Gisbert J, Mart\u00edn Argila C. \u00dalcera p\u00e9ptica e infecci\u00f3n por Helicobacter pylori. En: Asociaci\u00f3n Espa\u00f1ola de Gastroenterolog\u00eda, Ponce Garc\u00eda J., editor. Tratamiento de las enfermedades gastroenterol\u00f3gicas. Barcelona: Elsevier; 2011. p. 109-21."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-7-200904070-00105"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.4056"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-12-66"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"25. P\u00e9rez-Gisbert J, Calvet X, Ferrandiz J, et al. Clinical practice guideline on the management of patients with dyspepsia. Update 2012. Gastroenterol Hepatol. 2012; 35: 725.e1-38. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23186826","DOI":"10.1016\/j.gastrohep.2012.05.002"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"26. Dellon ES. Diagnosis and Management of Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2012; 10: 1066-78. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22728382","DOI":"10.1016\/j.cgh.2012.06.003"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.07.041"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310991"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.094912"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"30. Stabler SP. Vitamin B-12 Deficiency. N Engl J Med. 2013; 368: 149-60. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23697526","DOI":"10.1056\/NEJMcp1113996"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12697"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.280490"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2007.10.004"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2003.08.015"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"35. Force RW, Meeker AD, Cady PS, et al. Increased vitamin B-12 requirement associated with chronic acid suppression therapy. Ann Pharmacother. 2003; 37: 490-3. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12659601","DOI":"10.1345\/aph.1C037"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-3-199402010-00006"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00340-1"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1992.tb00553.x"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00087-4"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1080\/01639360903574734"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199206000-00005"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1996.27169000.x"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03601.x"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200109000-00023"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9880-7"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03658.x"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0980"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13194"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1996.20846000.x"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-014-0554-0"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20155"},{"key":"ref52","unstructured":"52. Sellapah S. An unusual side effect of omeprazole: case report. Br J Gen Pract. 1990; 40: 389-. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2265010"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.452"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03808.x"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3224"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.10.012"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e3182333820"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc066308"},{"key":"ref59","unstructured":"59. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Riesgo de hipomagnesemia asociado a los medicamentos inhibidores de la bomba de protones (IBP). Ref. MUH (FV), 27\/2011. 2011.Accesible en: http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2011\/docs\/NI-MUH_27-2011.pdf. [visitado 23\/12\/15]"},{"key":"ref60","unstructured":"60. FDA Drug Safety Communication. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Washington, DC: US. Food and Drug Administration; 2011. Accesible en: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm213206.htm."},{"key":"ref61","unstructured":"61. Administration TG. Risk of hypomagnesaemia with proton pump inhibitors. Medicines safety update Vol 2, Number 3. Australian prescriber. 2011; 34: 81. Accesible en: https:\/\/www.tga.gov.au\/publication-issue\/medicines-safety-update-vol-2-no-3-june-2011"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0112558"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1R556"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2015.1057800"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-006-0021-7"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.24.2947"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.071330"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.8.951"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-008-9170-1"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-008-9188-4"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.03.055"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.94"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-010-1337-8"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.09.028"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1410"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-014-9855-6"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2015.08.024"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3168-0"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e372"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"80. Adams AL, Black MH, Zhang JL, et al. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. Ann Epidemiol. 2014; 24: 286-90. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24507954","DOI":"10.1016\/j.annepidem.2014.01.004"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2279"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2014.05.019"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2026"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"84. Fraser LA, Leslie WD, Targownik LE, et al. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study. Osteoporos Int. 2013; 24: 1161-8. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22890365","DOI":"10.1007\/s00198-012-2112-9"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.20"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-009-0891-4"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-012-0406-9"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-012-0722-9"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1243"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.113"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"91. Yu EW, Bauer SR, Bain PA, et al. Proton Pump Inhibitors and Risk of Fractures: A Meta-Analysis of 11 International Studies. Am J Med. 2011; 124: 519-26. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21605729","DOI":"10.1016\/j.amjmed.2011.01.007"},{"key":"ref92","unstructured":"92. Yang S-D, Chen Q, Wei H-K, et al. Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis. Int J Clin Exp Med. 2015; 8: 4899-910. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26131063"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"93. Zhou B, Huang Y, Li H, et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2015. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26462494","DOI":"10.1007\/s00198-015-3365-x"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-199812010-00005"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.357"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2011"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.02.007"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.108"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.200"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1002\/PHAR.1007"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2344"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.5009\/gnl14135"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/321379"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-014-0030-y"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01275.x"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268815002332"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu628"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"108. Garc\u00eda Rodr\u00edguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol. 2007; 5: 1418-23. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18054750","DOI":"10.1016\/j.cgh.2007.09.010"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.108"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.179"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.09.030"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.42"},{"key":"ref113","unstructured":"113. FDA Drug Safety Communication. Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Washington, DC: US. Food and Drug Administration; 2012. Accesible en: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm290510.htm."},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.16.1955"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.167.9.950"},{"key":"ref116","doi-asserted-by":"crossref","unstructured":"116. Sarkar M, Hennessy S, Yang Y-X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008; 149: 391-8. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18794558","DOI":"10.7326\/0003-4819-149-6-200809160-00005"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04284.x"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.12.20"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0128004"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.092129"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-012-2211-5"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304738"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.109.029132"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1882-3"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M051"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.06.064"},{"key":"ref127","doi-asserted-by":"crossref","unstructured":"127. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med. 2010; 363: 1909-17. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20925534","DOI":"10.1056\/NEJMoa1007964"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61525-7"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.032912"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.04049.x"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.12.071"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04247.x"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.03.085"},{"key":"ref134","unstructured":"134. European Medicines Agency. Public statement: Interaction between clopidogrel and proton pump inhibitors. 2009; (29 may). Accesible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2009\/11\/WC500014409.pdf [visitado 23\/12\/15]"},{"key":"ref135","unstructured":"135. European Medicines Agency. Public statement: Interaction between clopidogrel and proton pump inhibitors (update). 2010; (17 mar). Accesible en: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2010\/03\/WC500076346.pdf [visitado 23\/12\/15]"},{"key":"ref136","unstructured":"136. Food and Drug Administration. FDA reminder to avoid concomitant use of Plavix (clopidogrel) and omeprazole (27 oct). 2010. Accesible en: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm231161.htm. [visitado 23\/12\/15]"},{"key":"ref137","unstructured":"137. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Interacci\u00f3n de clopidogrel con los inhibidores de la bomba de protones: actualizaci\u00f3n de la informaci\u00f3n y recomendaciones de uso (Nota informativa). 2010. Accesible en: http:\/\/www.aemps.gob.es\/informa\/notasInformativas\/medicamentosUsoHumano\/seguridad\/2010\/docs\/NI_2010-04_clopidogrel.pdf. [visitado 23\/12\/15]"},{"key":"ref138","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2010.12.033"},{"key":"ref139","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht042"},{"key":"ref140","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124653"},{"key":"ref141","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.05.021"},{"key":"ref142","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2015-000248"},{"key":"ref143","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002245"},{"key":"ref144","doi-asserted-by":"crossref","unstructured":"144. Weisz G, Smilowitz NR, Kirtane AJ, et al. Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study. Circ Cardiovasc Interv. 2015; 8: pii: e001952. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26458411","DOI":"10.1161\/CIRCINTERVENTIONS.114.001952"},{"key":"ref145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.05.017"},{"key":"ref146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135915"},{"key":"ref147","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302371"},{"key":"ref148","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.114.001177"},{"key":"ref149","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.114.001586"},{"key":"ref150","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.722"},{"key":"ref151","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.73"},{"key":"ref152","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.80"},{"key":"ref153","doi-asserted-by":"publisher","DOI":"10.4238\/2015.July.3.25"},{"key":"ref154","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9899-9"},{"key":"ref155","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02650.x"},{"key":"ref156","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2011.551891"},{"key":"ref157","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.11.019"},{"key":"ref158","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12065"},{"key":"ref159","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12210"},{"key":"ref160","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.53.2021"},{"key":"ref161","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/751921"},{"key":"ref162","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12875"},{"key":"ref163","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110503"},{"key":"ref164","doi-asserted-by":"crossref","unstructured":"164. O'Leary JG, Reddy KR, Wong F, et al. Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2015; 13: 753-9.e1-2. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25130937","DOI":"10.1016\/j.cgh.2014.07.060"},{"key":"ref165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.036"},{"key":"ref166","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000944"},{"key":"ref167","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12426"},{"key":"ref168","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12593"},{"key":"ref169","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2011.02643.x"},{"key":"ref170","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13061"},{"key":"ref171","unstructured":"171. Emre Y, Mesut S, Aylin Y, et al. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Expert Opin Drug Saf. 2015. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26635063"},{"key":"ref172","doi-asserted-by":"crossref","unstructured":"172. Honer Zu Siederdissen C, Maasoumy B, Marra F, et al. Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. Clin Infect Dis. 2015. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26611779","DOI":"10.1093\/cid\/civ973"},{"key":"ref173","doi-asserted-by":"crossref","unstructured":"173. Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med. 2016; 176: 238-46. Accesible en: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26752337","DOI":"10.1001\/jamainternmed.2015.7193"}],"container-title":["Revista Espa\u00f1ola de Enfermedades Digestivas"],"original-title":[],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T02:22:41Z","timestamp":1567736561000},"score":1,"resource":{"primary":{"URL":"https:\/\/online.reed.es\/fichaArticulo.aspx?iarf=683765748237-413275194166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":173,"URL":"https:\/\/doi.org\/10.17235\/reed.2016.4232\/2016","relation":{},"ISSN":["1130-0108"],"issn-type":[{"value":"1130-0108","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}